A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.
Osteoarthritis (OA) is the most common form of joint disease and the leading cause of pain in older people. OA often begins by age 40 and can worsen as we age with twenty-four percent (24.6%) of all adults, or 58.5 million people, having arthritis. (Katz, JAMA 2021) For those 65 years or older, half (50.4%) […]